Bulk Brucella abortus RB51 antigen intended for injectable cattle vaccine production is standardized by viable plate count before lyophilization. The downstream manufacture begins with thawed working seed lot material expanded in a stirred-tank bioreactor at 37°C under biosafety level 3 containment, followed by continuous centrifugation at 10,000×g and resuspension in a stabilizer matrix containing sucrose, sodium glutamate, and dextran. Industry compliance for the finished injectable product in the United States falls under USDA 9 CFR 113.65 for Brucella abortus vaccine, while international distribution commonly requires alignment with WOAH Terrestrial Manual Chapter 3.1.4 and, where the Brucella abortus S19 strain is used, Ph. Eur. monograph 0793. The formulation addition ratio is expressed not as a mass fraction but as a dose-specific viability target: the RB51 label dose for female calves of 4–12 months age is 1.0×10¹⁰ to 3.4×10¹⁰ CFU per 2.0 mL rehydrated dose, which drives the filling volume of the bulk antigen solution into Type I glass vials. Downstream production requires a sterile filling line with peristaltic or rotary piston pumps calibrated to deliver 2.0–6.0 mL per vial, followed by lyophilization in a freeze dryer with shelf temperature ramp from -45°C to +20°C at a chamber pressure of 80–150 µbar, and terminal residual moisture held below 2.0% by Karl Fischer titration. Terminal product types include lyophilized cake in 5-dose and 25-dose multi-dose vials with separate sterile diluent; the principal production bottleneck observed on commercial lines is cake collapse when the glass transition temperature of the sucrose-glutamate matrix is exceeded during primary drying.

How Is the Rev.1 Ovine/Caprine Dose Stabilized for Ocular and Subcutaneous Solutions?

Because the Rev.1 strain is administered by the conjunctival route in many small-ruminant eradication programs, the Brucella melitensis Rev.1 API is processed into a freeze-dried powder that is reconstituted either as an ophthalmic suspension or as a subcutaneous injection, with the target population being replacement lambs and kids of 3–6 months of age under WOAH Terrestrial Manual Chapter 3.1.4 and Ph. Eur. 0793 compliance. The addition ratio is based on the licensed viable count per dose: 1.0×10⁹ to 2.0×10⁹ CFU per animal is used for the ocular route, with the same range applied to the subcutaneous route in some national programs, and the reconstituted volume is 0.1 mL for conjunctival instillation rather than 1.0 mL for subcutaneous injection. Manufacturing involves blending the API with lactose and sodium glutamate, filling into single-dose vials at 1.0 mL fill volume before lyophilization, and terminal vacuum sealing under nitrogen. For ocular solutions, the downstream process must include a pre-filtration step with 0.22 µm sterilizing-grade filters for the diluent, while the live bacterial fraction cannot be filtered at that pore size and is instead aseptically filled after standardizing the concentration. Terminal product types include single-dose lyophilized powder with sterile diluent vials, pre-filled ophthalmic dropper bottles in national programs that permit liquid presentation, and 1.0 mL subcutaneous injection vials; a characteristic production problem is rapid loss of viability when the reconstituted suspension is held beyond 4–6 h at ambient temperature, which requires cold-chain distribution at 2–8°C.

Brucella suis S2 oral vaccination programs in East Asian swine and small-ruminant herds convert the API into dry premix and granule intermediates rather than sterile injectable dose forms. The governing standard for such oral live brucellosis vaccines is the manufacturer’s registration dossier under national veterinary biologics regulations, with manufacturing practice aligned to WOAH Terrestrial Manual Chapter 3.1.4 and current Good Manufacturing Practice for veterinary medicinal products. The addition ratio in the premix is derived from the target oral dose of 2.0×10¹⁰ CFU per pig, achieved by blending lyophilized API with calcium silicate or rice hull carrier to produce an intermediate premix with a viable count of 1.0×10⁹ CFU/g; the premix is then top-dressed or mixed into feed at a rate that delivers the target dose over 24 h. Downstream production handling for oral premix differs from injection because the live antigen is not sterile-filtered and the granulation process uses dry blending rather than wet granulation to avoid a heating step above 25°C; a horizontal ribbon blender with a working capacity of 500–1000 L is used, followed by sieving at 1.0 mm and packaging in multi-layer foil sachets. Terminal product types include 100 g and 500 g premix sachets, oral drench suspensions in 20 mL to 100 mL bottles, and feed-grade granules; the most common batch failure is uneven CFU distribution when mixing time is shortened below 15 min in high-humidity conditions above 60% RH.

When a Freeze-Dried Antigen Powder Is Converted into an Enteric-Coated Oral Tablet for Flock Vaccination

In a flock vaccination program, oral tablet presentation of live Brucella API is used where mass vaccination of small ruminants requires a stable, individually administered dosage form that avoids reconstitution and injection. The formulation route relies on lyophilized antigen powder dry-blended with microcrystalline cellulose, crospovidone, and magnesium stearate, followed by direct compression at low pressure; the addition ratio is determined by the required CFU per unit, typically 1.0×10⁹ to 5.0×10⁹ CFU per 1.0 g tablet for lamb and kid oral delivery under WOAH Terrestrial Manual Chapter 3.1.4 and current Good Manufacturing Practice for veterinary medicinal products. Because the live bacterium is sensitive to compression heat and moisture, the tableting process is run at 15–25°C and 20–35% RH, with a rotary tablet press speed below 25 rpm and a pre-compression force of 2–4 kN followed by main compression of 6–10 kN; the tablets are then enteric-coated in a side-vented pan coater with an aqueous methacrylic acid copolymer dispersion to a weight gain of 6–8%, providing gastric resistance and release at intestinal pH above 6.0. Terminal product types include blister-packed oral tablets of 1.0 g unit mass, capsules filled with enteric-coated granules, and orodispersible lyophilized tablets produced by freeze-drying directly in blister wells; capsule filling uses a dosator-type machine set to ±5% weight variation, and capsule shells are hydroxypropyl methylcellulose with moisture content below 5.0%.

When a regional animal health manufacturer licenses bulk Brucella vaccine API for multiple finishing steps, the powder is handled as a lyophilized intermediate rather than as a finished dosage unit. The API is supplied as a freeze-dried powder with a defined viable count per gram, typically controlled between 1.0×10¹⁰ and 5.0×10¹⁰ CFU/g, and is milled and sieved to a particle-size distribution of 90% < 150 µm before being blended with excipient carriers; this addition parameter permits downstream formulators to calculate unit-dose fill weights without additional titre adjustment. Compliance for bulk powder transfer rests on the receiving facility’s veterinary biologics establishment registration, with stability data generated under ICH Q1A or VICH GL3 conditions at 2–8°C and dry-powder moisture below 2.0%. The production process for the bulk powder includes fermentation harvest, continuous centrifugation, cryoprotectant blending, freeze-drying, low-shear milling with a pin mill, vacuum packaging in double polyethylene bags inside aluminum-laminate drums, and shipment under qualified cold-chain containers. Terminal product types arising from this bulk powder include reconstituted injectable vaccines, oral granules, capsules, and premix blends for multiple target species; the main operational boundary is that re-milling of the powder must be conducted at ≤25°C and ≤30% RH because the live Brucella API loses viability if the mill chamber temperature exceeds 35°C for more than 10 min.